Cumulative evidence has revealed that aberrant expression of ALDH1 is being evaluated as a potential novel prognostic marker in breast cancer (13), head and neck squamous cell carcinoma (7), ovarian cancer (9), and lung cancer (14). This evidence concerns the gene ALDH1A1 and lung cancer.